Genome-scale perturbation signatures from primary human CD4+ T cells improve genetics-based prioritization of immune drug targets
- 1University of Michigan Medical School, Ann Arbor, MI, USA
Abstract
While human genetic evidence improves drug program success, target selection largely relies on associational features. Even functional features are mainly observational, capturing disease associations rather than the consequence of perturbing genes in the disease-relevant human cell type. To move beyond association, we present IGNITE (Immune Genomics and fuNctional Integration for Target Enrichment), a framework that prioritizes immune drug targets by integrating human genetic priors with features from genome-scale perturb-seq in 22 million primary human CD4+ T cells and polarized T-helper subset differential expression. IGNITE is a semi-supervised machine learning model that applies positive-unlabeled learning to approved immune targets, then ranks 19,502 protein-coding genes to prioritize new candidates. In 727 in-trial genes held out from training, functional genomics increased target enrichment among the top 50 nominations from 2.7- to 4.8-fold for immune trial targets at any phase, and from 4.5- to 5.9-fold for targets in Phase III. These performance gains were immune-specific, as IGNITE outperformed genetic comparators on predicting immune-exclusive targets but not on cardiac-exclusive targets. Using temporal validation with labels frozen in 2014, IGNITE outperformed the genetics-only model in ranking 134 genes that subsequently entered immune trials. The functional genomics layer also surfaced two novel, pharmacologically tractable candidates, ELOVL6 and RUVBL1, elevating their rankings from outside the top 1,000 into the top 50. These findings highlight that perturbational signatures in the disease-relevant human cell type harbor target-relevant signals beyond human genetics, offering a generalizable route to indication-specific prioritization as perturbation atlases expand. Full IGNITE scores are publicly available at https://ignite.eecs.umich.edu/
Related
- Network and behavioral signatures of postpartum behavioral deficits improve with a neurosteroid-based treatment
- Strategies to improve neurite outgrowth from primary neurons ingelatin methacrylate hydrogels polymerized with visible lightexposure inside a microscale 3D model
- PTEN Deletion, mTORC1 Signatures and CAD Expression in Primary Prostate Cancer: Protein-Level Data and the Role of ERG Fusion
- CCL24 Blockade with Nebokitug Modulates Inflammation and Fibrosis Signatures in Primary Sclerosing Cholangitis
- The Enigma of Finnish and Sardinian Type 1 Diabetes Incidence: Where Population History Meets Genetics
BibTeX
@misc{han2026genomescale,
title = {{Genome-scale perturbation signatures from primary human CD4+ T cells improve genetics-based prioritization of immune drug targets}},
author = {A. L. Han and M. Slotnik and D. A. Fox and R. S. Dhindsa and J. E. Gudjonsson and J. M. Kahlenberg and J. Welch},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.12.748195},
url = {https://www.biorxiv.org/content/10.64898/2026.09.12.748195v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Genome-scale perturbation signatures from primary human CD4+ T cells improve genetics-based prioritization of immune drug targets
AU - A. L. Han
AU - M. Slotnik
AU - D. A. Fox
AU - R. S. Dhindsa
AU - J. E. Gudjonsson
AU - J. M. Kahlenberg
AU - J. Welch
PY - 2026
DA - 2026/09/12
PB - bioRxiv
DO - 10.64898/2026.09.12.748195
UR - https://www.biorxiv.org/content/10.64898/2026.09.12.748195v1
AB - While human genetic evidence improves drug program success, target selection largely relies on associational features. Even functional features are mainly observational, capturing disease associations rather than the consequence of perturbing genes in the disease-relevant human cell type. To move beyond association, we present IGNITE (Immune Genomics and fuNctional Integration for Target Enrichment), a framework that prioritizes immune drug targets by integrating human genetic priors with features from genome-scale perturb-seq in 22 million primary human CD4+ T cells and polarized T-helper subset differential expression. IGNITE is a semi-supervised machine learning model that applies positive-unlabeled learning to approved immune targets, then ranks 19,502 protein-coding genes to prioritize new candidates. In 727 in-trial genes held out from training, functional genomics increased target enrichment among the top 50 nominations from 2.7- to 4.8-fold for immune trial targets at any phase, and from 4.5- to 5.9-fold for targets in Phase III. These performance gains were immune-specific, as IGNITE outperformed genetic comparators on predicting immune-exclusive targets but not on cardiac-exclusive targets. Using temporal validation with labels frozen in 2014, IGNITE outperformed the genetics-only model in ranking 134 genes that subsequently entered immune trials. The functional genomics layer also surfaced two novel, pharmacologically tractable candidates, ELOVL6 and RUVBL1, elevating their rankings from outside the top 1,000 into the top 50. These findings highlight that perturbational signatures in the disease-relevant human cell type harbor target-relevant signals beyond human genetics, offering a generalizable route to indication-specific prioritization as perturbation atlases expand. Full IGNITE scores are publicly available at https://ignite.eecs.umich.edu/
ER -